Homologous or heterologous COVID-19 vaccine schemes: Comparison of immune responses and side effects

Basit Öğe Kaydı
dc.authorid0000-0001-7275-8724
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorDinç, Harika Öykü
dc.contributor.authorİnanç Balkan, İlker
dc.contributor.authorCan, Günay
dc.contributor.authorKeskin, Elif
dc.contributor.authorÇolak, Hatice
dc.contributor.authorDaşdemir, Ferhat Osman
dc.contributor.authorAydoğan, Okan
dc.contributor.authorBudak, Beyhan
dc.contributor.authorYıldız Kaya, Sibel
dc.contributor.authorKocazeybek, Bekir
dc.contributor.authorSaltoğlu, Neşe
dc.date.accessioned2023-08-22T07:06:17Z
dc.date.available2023-08-22T07:06:17Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Mikrobiyoloji Ana Bilim Dalı
dc.description.abstractReal-life data are needed regarding the appropriate time and selection of vaccination strategies, homologous or heterologous. We aimed to compare neutralizing antibody levels and side effects in different vaccination schemes. The study included 310 Health Care Workers (HCWs) vaccinated with 5 different schemes. Antispike/RBD IgG levels were measured between 28 and 60 days after the last dose. Side effects in participants were recorded, and pharmacovigilance records were reviewed from the outpatient vaccine clinic. Mean age of the participants was 38 ± 11 years of whom 226 (72.9%) were female, and 84 (27.1%) were male. After booster doses, increasing antibody levels were detected in all groups. Mean antibody levels were detected to be statistically lower in 3 doses of inactivated vaccines group. The side effects were no significant difference between groups. Booster dose administration with mRNA vaccines stands out as the most accurate strategy for those at risk of contracting severe COVID-19 and HCWs caring for this population.
dc.description.sponsorshipIU-Cerrahpaşa Scientific Research Projects Uniten_US
dc.identifier.citationKaraali, R., Dinç, H. Ö., İnanç Balkan, İ., Can, G., Keskin, E., Çolak, H. ... Saltoğlu, N. (2023). Homologous or heterologous COVID-19 vaccine schemes: Comparison of immune responses and side effects. Diagnostic Microbiology and Infectious Disease, 107(2). https://dx.doi.org/10.1016/j.diagmicrobio.2023.116017
dc.identifier.doi10.1016/j.diagmicrobio.2023.116017
dc.identifier.issn0732-8893
dc.identifier.issn1879-0070
dc.identifier.issue2
dc.identifier.pmid37562205
dc.identifier.scopus2-s2.0-85167450311
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://dx.doi.org/10.1016/j.diagmicrobio.2023.116017
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11352
dc.identifier.volume107
dc.identifier.wos001059034800001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAydoğan, Okan
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofDiagnostic Microbiology and Infectious Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectBNT162b2 mRNA
dc.subjectInactivated CoronaVac
dc.subjectNeutralizing Antibody
dc.subjectSide Effects
dc.subjectVaccine
dc.subjectVaccine Schemes
dc.titleHomologous or heterologous COVID-19 vaccine schemes: Comparison of immune responses and side effects
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aydogan-Okann-2023.pdf
Boyut:
469.78 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu